Advancing New Medicines for Patients with Cancer

At Verastem Oncology, we leverage our expertise in translational research, strategic partnerships, and a deep understanding of cancer treatment pathways to identify, develop and deliver targeted and effective options to address unmet needs.

Learn more about our areas of focus

View all news releases

Our Pipeline

Our pipeline includes potential cancer therapies targeting malignant cells both directly and through modulation of the tumor microenvironment. Our Verastem Oncology programs include:

RAF/MEK inhibitor (VS-6766)
Focal adhesion kinase (FAK) inhibitor (defactinib)

All clinical stage molecules are being evaluated in multiple clinical studies for the treatment of patients with several different cancer types.

View Our Pipeline

Disease Area Focus

Mature Woman Discussing Problems With Counselor

Ovarian cancer

Ovarian cancer is a disease in which, depending on the type and stage of the disease, malignant (cancerous) cells are found inside, near, or on the outer layer of the ovaries. In women ages 35-74, ovarian cancer is the fifth leading cause of cancer-related deaths. An estimated one woman in 75 will develop ovarian cancer during her lifetime.

Ovarian cancer may not cause any specific symptoms, particularly in its early stages. When it does cause symptoms, these may be nonspecific and vague.

Our development program is focused on a subset of this disease, low-grade serous ovarian cancer (LGSOC). LGSOC is a slow-growing cancer with a high mortality rate that comprise 5-10% of serous ovarian cancers and 6-8% of all ovarian cancers, and has a significant prevalence of KRAS mutations which occur in approximately one third of patients. The remaining KRAS wild-type patients include those with mutations in NRAS or BRAF. There are an estimated 1,000 to 2,000 patients in the U.S. and 15,000 to 30,000 worldwide diagnosed with LGSOC each year. Approximately half of those diagnosed are in their 20s-40s. LGSOC has a median survival rate of 10 years, with 85% of patients experiencing recurrence and enduring severe pain and complications as the disease progresses. Chemotherapy is the standard of care for this disease.

Learn more about our phase 2 clinical trial (RAMP 201) in recurrent LGSOC.

Non-small cell lung cancer (NSCLC)

About 80-85% of lung cancers are non-small cell lung cancer (NSCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants.

NSCLC arises from the epithelial cells of the lung within the central bronchi to terminal alveoli. The histological type of NSCLC correlates with site of origin, reflecting the variation in respiratory tract epithelium of the bronchi to alveoli. Squamous cell carcinoma usually originates near a central bronchus. Adenocarcinoma and bronchioloalveolar carcinoma usually originate in peripheral lung tissue.

KRAS mutation occurs in ~25% of NSCLC adenocarcinoma patients. Two of the most common types of KRAS mutations are G12V, which are present in approximately 7% of NSCLC and G12C, which occur in approximately 13% of NSCLC. Studies suggest that these types of KRAS mutations differ in clinical characteristics and response to traditional treatments such as chemotherapy.

Learn more about our phase 2 clinical trial (RAMP 202) in KRAS mutant NSCLC.